• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma.

作者信息

Ladetto M, Ferrero S, Drandi D, Festuccia M, Patriarca F, Mordini N, Cena S, Benedetto R, Guarona G, Ferrando F, Brunello L, Ghione P, Boccasavia V, Fanin R, Omedè P, Giaccone L, Palumbo A, Passera R, Boccadoro M, Bruno B

机构信息

Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy.

Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.

出版信息

Leukemia. 2016 May;30(5):1211-4. doi: 10.1038/leu.2015.269. Epub 2015 Oct 6.

DOI:10.1038/leu.2015.269
PMID:26437784
Abstract
摘要

相似文献

1
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma.新诊断多发性骨髓瘤非清髓性同种异体移植后微小残留病的前瞻性分子监测
Leukemia. 2016 May;30(5):1211-4. doi: 10.1038/leu.2015.269. Epub 2015 Oct 6.
2
Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells.多发性骨髓瘤的分子与临床缓解：造血细胞自体及异基因移植的作用
J Clin Oncol. 1999 Jan;17(1):208-15. doi: 10.1200/JCO.1999.17.1.208.
3
Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma.非清髓性预处理后无关供者造血细胞移植治疗高危多发性骨髓瘤患者
Eur J Haematol. 2007 Apr;78(4):330-7. doi: 10.1111/j.1600-0609.2007.00816.x. Epub 2007 Feb 27.
4
Pretransplant induction regimens for multiple myeloma.多发性骨髓瘤的移植前诱导方案。
Biol Blood Marrow Transplant. 2015 Feb;21(2):200-1. doi: 10.1016/j.bbmt.2014.12.013. Epub 2014 Dec 19.
5
Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.多发性骨髓瘤患者外周血中浆细胞和造血祖细胞的同时动员。
J Hematother. 1996 Aug;5(4):339-49. doi: 10.1089/scd.1.1996.5.339.
6
Role of allogeneic stem cell transplantation in multiple myeloma.异基因干细胞移植在多发性骨髓瘤中的作用。
Semin Hematol. 2009 Apr;46(2):158-65. doi: 10.1053/j.seminhematol.2009.02.001.
7
Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation.基于聚合酶链反应检测接受异基因干细胞移植的多发性骨髓瘤患者的微小残留病
Haematologica. 2000 Sep;85(9):930-4.
8
Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation.微型-中型-大型？异基因干细胞移植后如何利用移植物抗骨髓瘤效应并实现分子缓解目标。
Leukemia. 2007 Sep;21(9):1851-8. doi: 10.1038/sj.leu.2404775. Epub 2007 Jun 14.
9
[Hematopoietic stem cell transplantation for multiple myeloma].[多发性骨髓瘤的造血干细胞移植]
Rinsho Ketsueki. 2009 Oct;50(10):1420-6.
10
Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.采用体内T细胞清除及辅助性递增剂量供体淋巴细胞输注的低强度移植治疗化疗敏感型骨髓瘤：移植物抗肿瘤活性疗效有限
Biol Blood Marrow Transplant. 2003 Apr;9(4):257-65. doi: 10.1053/bbmt.2003.50009.

引用本文的文献

1
Autologous-allogeneic autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II study.自体-异基因 自体串联干细胞移植和沙利度胺维持治疗 60 岁以下多发性骨髓瘤患者：一项前瞻性、Ⅱ期研究。
Haematologica. 2024 May 1;109(5):1469-1479. doi: 10.3324/haematol.2023.282920.
2
IL5RA as an immunogenic cell death-related predictor in progression and therapeutic response of multiple myeloma.IL5RA 作为多发性骨髓瘤进展和治疗反应的免疫原性细胞死亡相关预测因子。
Sci Rep. 2023 May 26;13(1):8528. doi: 10.1038/s41598-023-35378-z.
3

本文引用的文献

1
Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.多发性骨髓瘤中的异基因干细胞移植：免疫疗法与新药
Expert Opin Biol Ther. 2015 Jun;15(6):857-72. doi: 10.1517/14712598.2015.1036735. Epub 2015 Apr 12.
2
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival.GIMEMA VEL-03-096 试验中接受 ASCT 后 VTD 巩固治疗的 MM 患者的长期结果：MRD 动力学对生存的影响。
Leukemia. 2015 Mar;29(3):689-95. doi: 10.1038/leu.2014.219. Epub 2014 Jul 16.
3
Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis.
多发性骨髓瘤中 ecto-钙网蛋白的表达与抗肿瘤免疫反应失败和不良预后相关。
Oncoimmunology. 2022 Nov 1;11(1):2141973. doi: 10.1080/2162402X.2022.2141973. eCollection 2022.
4
Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches.多发性骨髓瘤中的微小残留病：免疫治疗方法的现状与未来应用
Front Oncol. 2020 May 27;10:860. doi: 10.3389/fonc.2020.00860. eCollection 2020.
5
Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?用于多发性骨髓瘤临床管理的下一代测序：准备好进入黄金时代了吗？
Front Oncol. 2020 Feb 25;10:189. doi: 10.3389/fonc.2020.00189. eCollection 2020.
6
Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis.新诊断多发性骨髓瘤研究中微小残留病灶状态作为无进展生存期替代终点的Meta 分析。
Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):e30-e37. doi: 10.1016/j.clml.2019.09.622. Epub 2019 Oct 9.
7
Comparison of outcomes after human leukocyte antigen-matched and haploidentical hematopoietic stem-cell transplantation for multiple myeloma.人类白细胞抗原匹配和单倍体造血干细胞移植治疗多发性骨髓瘤的结局比较。
Chin Med J (Engl). 2019 Aug 5;132(15):1765-1772. doi: 10.1097/CM9.0000000000000341.
8
Immunogenic Cell Death and Immunotherapy of Multiple Myeloma.多发性骨髓瘤的免疫原性细胞死亡与免疫治疗
Front Cell Dev Biol. 2019 Apr 16;7:50. doi: 10.3389/fcell.2019.00050. eCollection 2019.
9
The stepchild in myeloma treatments: is allogeneic transplantation not so bad after all?骨髓瘤治疗中的继子：异基因移植终究并非那么糟糕？
Haematologica. 2019 Feb;104(2):222-225. doi: 10.3324/haematol.2018.206987.
10
Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.自体-异体造血干细胞移植序贯治疗多发性骨髓瘤的长期随访。
Haematologica. 2019 Feb;104(2):380-391. doi: 10.3324/haematol.2018.200253. Epub 2018 Sep 27.
硼替佐米联合减低强度预处理方案及异基因造血干细胞移植治疗高危多发性骨髓瘤的Ⅱ期临床研究
Br J Haematol. 2013 Aug;162(4):474-82. doi: 10.1111/bjh.12410. Epub 2013 Jun 15.
4
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.自体/减低强度异基因干细胞移植与多发性骨髓瘤的自体移植：EBMT-NMAM2000 研究的长期结果。
Blood. 2013 Jun 20;121(25):5055-63. doi: 10.1182/blood-2012-11-469452. Epub 2013 Mar 12.
5
Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.高危细胞遗传学和分子缓解对多发性骨髓瘤患者自体-异基因串联移植后长期无病生存的影响。
Biol Blood Marrow Transplant. 2013 Mar;19(3):398-404. doi: 10.1016/j.bbmt.2012.10.008. Epub 2012 Oct 16.
6
Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.自体造血干细胞移植继以异基因或自体造血干细胞移植治疗多发性骨髓瘤患者（BMT CTN 0102）：一项 3 期生物学任务试验。
Lancet Oncol. 2011 Dec;12(13):1195-203. doi: 10.1016/S1470-2045(11)70243-1. Epub 2011 Sep 29.
7
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma.新诊断骨髓瘤患者非清髓性异基因移植与自体移植的长期随访比较。
Blood. 2011 Jun 16;117(24):6721-7. doi: 10.1182/blood-2011-03-339945. Epub 2011 Apr 13.
8
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.硼替佐米、沙利度胺和地塞米松巩固治疗自体移植后骨髓瘤患者的主要肿瘤缩小和持续分子缓解。
J Clin Oncol. 2010 Apr 20;28(12):2077-84. doi: 10.1200/JCO.2009.23.7172. Epub 2010 Mar 22.
9
A comparison of allografting with autografting for newly diagnosed myeloma.新诊断骨髓瘤同种异体移植与自体移植的比较。
N Engl J Med. 2007 Mar 15;356(11):1110-20. doi: 10.1056/NEJMoa065464.
10
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.通过Ig/TCR基因重排分析微小残留病：实时定量PCR数据解读指南
Leukemia. 2007 Apr;21(4):604-11. doi: 10.1038/sj.leu.2404586. Epub 2007 Feb 8.